Ncardia Introduces the Xpress.4U™ LightPace Cor.4U® Kit to Simplify Pacing of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes
28 September, 2018
For the first time, a single kit including all required reagents, cells and validated protocol
Efficient technology enabling non-toxic introduction of a light-sensitive ion-channel into Cor.4U® Cardiomyocytes
Kit eliminates need for imprecise correction formulas normally required for data interpretation
Cologne, Germany, 1st October 2018 – Ncardia announced today the launch of the Xpress.4U™ LightPace Cor.4U® Kit. This new solution is a validated kit and protocol to perform optical pacing of cardiomyocytes in drug discovery and cardiotoxicity safety studies. By bundling the Xpress.4U technology, light-sensitive ion channel mRNA, and Cor.4U Cardiomyocytes, this specially designed kit simplifies and improves the application of optical pacing of human induced pluripotent stem cell-derived cardiomyocytes.
Traditionally, the study of compound effects on cardiomyocyte electrophysiologic parameters is complicated by natural variations in the beat rate of cells. To overcome this challenge, pacing of hiPSC-derived cardiomyocytes can be achieved by blue light pulses after introducing a light-sensitive ion channel into the hiPSC-derived cardiomyocytes. The Xpress.4U™ LightPace Cor.4U® Kit enables pacing with efficient and non-toxic introduction of channelrhodopsin-2 into Cor.4U® Cardiomyocytes using Xpress.4U™ Technology.
“Controlling beat rate by optical pacing enables a more precise and in-depth analysis of cardioactive compound effects and empower safety pharmacologists to compare their safety assessment studies over the years.” said Mieke Doornbos, Product Marketing Manager at Ncardia. “This kit now provides an easy access to this application without commonly seen artefacts.”
The Xpress.4U™ LightPace Cor.4U® Kit extends Ncardia’s broad portfolio of products and services supporting safety and efficacy studies, including cardiovascular services from disease modeling to high-throughput drug efficacy screening, as well as a broad range of cardiac safety and toxicity services.
About the Xpress.4U™ LightPace Cor.4U® Kit
TheXpress.4U™ LightPace Cor.4U® Kit is the only kit available that enables optogenetic pacing for everyone working with Cor.4U® Cardiomyocytes. The package includes LightPace mRNA, Neutralization Buffer, Liposomes, Dilution Buffer, Cor.4U® Cardiomyocytes, Cor.4U® Complete Culture Medium and ready-to-go protocol.
Xpress.4U™ LightPace Video
Ncardia is convinced that stem cell technology will help give patients faster access to better and safer medicines by improving the drug discovery and development process. The company develops and produces highly predictive human cellular assay systems for safety and efficacy testing of drug candidates. Ncardia is based in Belgium, the Netherlands, Germany and the USA. The company is privately held and established following the merger of Pluriomics and Axiogenesis.
Dr Steven Dublin
Phone: +49 15 754743 427